Home ETF List About

ETF Holdings Breakdown of CRSP

Stock NameCrispr Therapeutics AG
TickerCRSP(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINCH0334081137
LEI506700O6IRRIQLT3W370

CRSP institutional holdings

The following institutional investment holdings of CRSP have been identified

Date ETF ISIN/Name Num Shares Book value
2025-10-17 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 25,322USD 1,751,016
2025-10-17 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 57,601USD 3,983,109
2025-10-17 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 57,601USD 3,983,109
2025-10-17 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 57,059USD 3,945,630 -3.9%
2025-10-17 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 441USD 30,495 -3.9%
Total =198,024 USD 13,693,359
Book value of shares is calculated on the adjusted close price of each day (row).

News associated with CRSP

Mitsubishi UFJ Asset Management Co. Ltd. Purchases 473 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)
Mitsubishi UFJ Asset Management Co. Ltd. raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,725 shares of the company’s stock after buying an additional 473 […] - 2025-08-15 04:46:59
Arkadios Wealth Advisors Has $382,000 Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)
Arkadios Wealth Advisors decreased its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 7.6% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 11,238 shares of the company’s stock after selling 923 shares during the period. Arkadios Wealth Advisors’ holdings in CRISPR Therapeutics […] - 2025-08-06 06:46:57
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by Envestnet Asset Management Inc.
Envestnet Asset Management Inc. boosted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 21.5% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 68,058 shares of the company’s stock after acquiring an additional 12,025 shares during the period. Envestnet […] - 2025-07-29 04:09:03
Bank of New York Mellon Corp Boosts Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)
Bank of New York Mellon Corp increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 1.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 77,702 shares of the company’s stock after acquiring an additional 1,133 shares during […] - 2025-07-28 04:22:49
Private Advisor Group LLC Increases Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)
Private Advisor Group LLC increased its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 27.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 108,418 shares of the company’s stock after buying an additional 23,382 shares during the quarter. […] - 2025-07-23 06:23:04
Allworth Financial LP Has $393,000 Position in CRISPR Therapeutics AG (NASDAQ:CRSP)
Allworth Financial LP lowered its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 23.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 11,560 shares of the company’s stock after selling 3,518 shares during the quarter. Allworth Financial LP’s holdings […] - 2025-07-15 06:16:47
CRISPR Therapeutics AG (NASDAQ:CRSP) Stake Lifted by Axxcess Wealth Management LLC
Axxcess Wealth Management LLC increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.0% in the first quarter, Holdings Channel.com reports. The institutional investor owned 10,309 shares of the company’s stock after acquiring an additional 393 shares during the period. Axxcess Wealth Management LLC’s holdings in CRISPR Therapeutics were worth […] - 2025-07-14 05:45:01
Traders Purchase Large Volume of Call Options on CRISPR Therapeutics (NASDAQ:CRSP)
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock investors bought 10,886 call options on the company. This represents an increase of approximately 49% compared to the typical daily volume of 7,308 call options. CRISPR Therapeutics Trading Down 1.8% NASDAQ CRSP opened at $59.00 on […] - 2025-07-11 02:50:55
CRISPR Therapeutics (NASDAQ:CRSP) Given “Buy” Rating at Needham & Company LLC
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at Needham & Company LLC in a research report issued on Tuesday,Benzinga reports. They presently have a $81.00 target price on the stock. Needham & Company LLC’s price objective would suggest a potential upside of 34.82% from the stock’s […] - 2025-07-10 04:01:25
Vontobel Holding Ltd. Trims Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)
Vontobel Holding Ltd. lessened its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 15.4% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 12,741 shares of the company’s stock after selling 2,327 shares during the quarter. Vontobel Holding Ltd.’s holdings […] - 2025-07-08 05:21:04
Spire Wealth Management Has $57,000 Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)
Spire Wealth Management reduced its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 15.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,670 shares of the company’s stock after selling 300 shares during the period. Spire Wealth Management’s […] - 2025-07-02 04:46:55
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $69.53 Average Target Price from Analysts
Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have earned a consensus recommendation of “Hold” from the seventeen brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and nine have issued a buy recommendation on the company. […] - 2025-06-24 02:54:46
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Bought by Farther Finance Advisors LLC
Farther Finance Advisors LLC lifted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 46.7% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,626 shares of the company’s stock after purchasing an additional 1,792 […] - 2025-06-20 04:29:03
California State Teachers Retirement System Sells 689 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)
California State Teachers Retirement System lowered its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 1.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 69,742 shares of the company’s stock after selling 689 shares during the period. California State […] - 2025-06-06 05:06:55
Two Sigma Advisers LP Increases Position in CRISPR Therapeutics AG (NASDAQ:CRSP)
Two Sigma Advisers LP lifted its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 50.4% during the 4th quarter, Holdings Channel.com reports. The fund owned 84,800 shares of the company’s stock after acquiring an additional 28,400 shares during the period. Two Sigma Advisers LP’s holdings in CRISPR Therapeutics were worth $3,338,000 as of […] - 2025-05-27 05:30:57
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of “Moderate Buy” by Analysts
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eighteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and ten have assigned a buy recommendation […] - 2025-05-27 03:06:46
Ameriprise Financial Inc. Has $8.07 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)
Ameriprise Financial Inc. lifted its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 205,173 shares of the company’s stock after acquiring an additional 18,412 shares during the period. Ameriprise Financial Inc.’s holdings in CRISPR Therapeutics were worth $8,072,000 as of its most recent […] - 2025-05-22 04:35:07
BNP Paribas Financial Markets Has $3.27 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)
BNP Paribas Financial Markets decreased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 5.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 82,994 shares of the company’s stock after selling 4,962 shares during the quarter. BNP […] - 2025-05-16 05:08:54
CRISPR Therapeutics AG (NASDAQ:CRSP) Stake Decreased by Mercer Global Advisors Inc. ADV
Mercer Global Advisors Inc. ADV lessened its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 13.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,980 shares of the company’s stock after selling 1,598 shares during […] - 2025-05-15 05:10:56
Barclays Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $42.00
CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price target lowered by Barclays from $56.00 to $42.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has an equal weight rating on the stock. Several other equities analysts have also recently commented on the stock. Truist Financial boosted their price […] - 2025-05-12 05:46:49
Dimensional Fund Advisors LP Has $37.28 Million Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)
Dimensional Fund Advisors LP boosted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 14.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 947,301 shares of the company’s stock after purchasing an additional 122,695 shares during the quarter. Dimensional […] - 2025-05-05 05:20:52
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Rating of “Hold” by Analysts
Shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) have received an average rating of “Hold” from the twenty-one research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and eleven have issued a buy recommendation on […] - 2025-05-02 04:20:50
CRISPR Therapeutics AG (NASDAQ:CRSP) Position Raised by NewEdge Advisors LLC
NewEdge Advisors LLC grew its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 28.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 7,420 shares of the company’s stock after purchasing an additional 1,622 shares during the quarter. NewEdge Advisors LLC’s […] - 2025-05-01 05:37:08
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by Invesco Ltd.
Invesco Ltd. raised its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 6.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 33,790 shares of the company’s stock after purchasing an additional 2,010 shares during the period. Invesco Ltd.’s holdings in CRISPR […] - 2025-05-01 04:42:52
Raymond James Financial Inc. Invests $3.23 Million in CRISPR Therapeutics AG (NASDAQ:CRSP)
Raymond James Financial Inc. bought a new position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 82,095 shares of the company’s stock, valued at approximately $3,231,000. A number of other institutional investors […] - 2025-04-28 04:51:03
Legal & General Group Plc Has $3.85 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)
Legal & General Group Plc trimmed its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 8.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 97,804 shares of the company’s stock after selling 9,121 shares during the quarter. Legal & General […] - 2025-04-23 05:19:07
Wells Fargo & Company MN Buys 17,094 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)
Wells Fargo & Company MN increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 8.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 220,123 shares of the company’s stock after purchasing an additional 17,094 shares during the quarter. Wells Fargo & […] - 2025-04-18 04:36:51
Geode Capital Management LLC Sells 7,346 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)
Geode Capital Management LLC lessened its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 0.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 1,000,868 shares of the company’s stock after selling 7,346 shares during the period. Geode Capital Management LLC’s holdings in CRISPR Therapeutics were worth $39,412,000 as of its […] - 2025-04-16 04:38:58
Norges Bank Makes New $17.46 Million Investment in CRISPR Therapeutics AG (NASDAQ:CRSP)
Norges Bank acquired a new position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 443,536 shares of the company’s stock, valued at approximately $17,458,000. Norges Bank owned about 0.52% of CRISPR Therapeutics as of its most recent filing with […] - 2025-04-08 05:19:03
Mitsubishi UFJ Asset Management Co. Ltd. Raises Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)
Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 7.6% in the fourth quarter, HoldingsChannel reports. The firm owned 5,252 shares of the company’s stock after buying an additional 372 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in CRISPR Therapeutics […] - 2025-04-04 05:12:57

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.